Horizon Pharma to Acquire Raptor Pharmaceuticals
Horizon Pharma will acquire Raptor Pharmaceuticals with the transaction expected to close in the fourth quarter of 2016.
On Sept. 12, 2016, Horizon Pharma announced that it will acquire Raptor Pharmaceuticals. The companies have entered into a definitive merger agreement under which Horizon will acquire all of the issued and outstanding shares of Raptor, the companies said in a press announcement. The diluted equity value of the remaining and outstanding shares of the company is approximately $800 million. The transaction is expected to close in the fourth quarter of 2016.
This acquisition will add Procysbi delayed-release capsules and Quinsair, aerosolized form of levofloxacin, to Horizon’s portfolio. In addition, Horizon says, the acquisition of Raptor diversifies the company’s revenue with 11 medicines across three business units, orphan, rheumatology, and primary care. Raptor's previously disclosed total net sales guidance for full-year 2016 is $125 million to $135 million.
Source: Horizon Pharma
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
